AMLad: Acute Myeloid Leukaemia agreement data
In TDIagree: Assessment of Agreement using the Total Deviation Index
AMLad R Documentation
Acute Myeloid Leukaemia agreement data
Description
Acute myeloid leukaemia (AML) is a type of cancer that starts in the blood-forming cells of the bone marrow.
While in adults it is the most common type of leukaemia, it is much rarer in children, accounting for
15-20% percent of paediatric leukaemia cases, which translates to 8 cases per year for every million children
under the age of 15 years.
Minimal residual disease (MRD) is the percentage of cancer cells that remain in a person
either during or after treatment when the patient is in remission (no symptoms or signs of disease). MRD aids
in identifying high-risk patients so therapy can be intensified in them while deintensification of
therapy can prevent long-term sequelae of chemotherapy in low-risk category patients.
MRD describes disease that can be detected using techniques other than traditional morphology, including
molecular methods such as polymerase chain reaction (PCR) and immunological methods such as flow cytometry
(FCM) (Chattaerjee et al., 2016).
This dataset is adapted from the Childhood Leukemia: Overcoming distance between South America
and Europe Regions (CLOSER) project, whose goal was to decrease the gap between Europe and Latin America in terms
of the diagnosis, monitoring, survival, and quality of life of patients with childhood leukaemia and their caregivers.
See Source for further information on the project. The dataset contains data from 116 paediatric patients
diagnosed with AML, in which the MRD was measured twice after treatment initiation by the methods PCR and FCM.
Usage
AMLad
Format
A data frame in long format with the following columns:
id: Patient identifier
met: Method to quantify MRD (PCR or FCM)
rep: Replicate (1 = first, 2 = second)
mrd: MRD (%)
Source
References
Chatterjee, T., Mallhi, R. S., & Venkatesan, S. (2016). Minimal residual disease detection using flow cytometry: Applications in acute leukemia. Medical Journal Armed Forces India, 72(2), 152-156.
TDIagree documentation built on June 18, 2025, 9:10 a.m.
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
| AMLad | R Documentation |
Acute Myeloid Leukaemia agreement data
Description
Acute myeloid leukaemia (AML) is a type of cancer that starts in the blood-forming cells of the bone marrow. While in adults it is the most common type of leukaemia, it is much rarer in children, accounting for 15-20% percent of paediatric leukaemia cases, which translates to 8 cases per year for every million children under the age of 15 years.
Minimal residual disease (MRD) is the percentage of cancer cells that remain in a person either during or after treatment when the patient is in remission (no symptoms or signs of disease). MRD aids in identifying high-risk patients so therapy can be intensified in them while deintensification of therapy can prevent long-term sequelae of chemotherapy in low-risk category patients.
MRD describes disease that can be detected using techniques other than traditional morphology, including molecular methods such as polymerase chain reaction (PCR) and immunological methods such as flow cytometry (FCM) (Chattaerjee et al., 2016).
This dataset is adapted from the Childhood Leukemia: Overcoming distance between South America and Europe Regions (CLOSER) project, whose goal was to decrease the gap between Europe and Latin America in terms of the diagnosis, monitoring, survival, and quality of life of patients with childhood leukaemia and their caregivers. See Source for further information on the project. The dataset contains data from 116 paediatric patients diagnosed with AML, in which the MRD was measured twice after treatment initiation by the methods PCR and FCM.
Usage
AMLad
Format
A data frame in long format with the following columns:
| id: | Patient identifier |
| met: | Method to quantify MRD (PCR or FCM) |
| rep: | Replicate (1 = first, 2 = second) |
| mrd: | MRD (%) |
Source
References
Chatterjee, T., Mallhi, R. S., & Venkatesan, S. (2016). Minimal residual disease detection using flow cytometry: Applications in acute leukemia. Medical Journal Armed Forces India, 72(2), 152-156.
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
Embedding an R snippet on your website
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.